Here are three things to know.
1. The agency approved Erleada to treat nonmetastatic prostate cancer that does not respond to hormone therapy.
2. Erleada represents the first FDA-approved treatment for this form of cancer.
3. In a recent clinical trial of 1,207 prostate cancer patients, Erleada reduced the risk of distant metastasis or death by 72 percent compared to a placebo.
4. Erleada’s list price will be about $10,920 per month, according to Reuters.
More articles on supply chain:
FDA greenlights Teligent’s topical steroid: 3 things to know
8 initiatives FDA would pursue under FY 2018 budget
FDA clears seizure-monitoring smartwatch
